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Abstract WSL-1/TRAMP (DR3) is a member of the tumour
necrosis factor (TNF) receptor superfamily which exhibits effects
on NF-UB activation and apoptosis. TWEAK, a novel TNF-
related molecule, has been proposed as the ligand for this
receptor. Utilising both human and murine TWEAK ligand, it is
shown that TWEAK and WSL-1/TRAMP do not interact in an
in vitro binding assay and that TWEAK binds strongly to cells
that do not express WSL-1/TRAMP on the cell surface.
Biological activity of TWEAK is also observed in these cells.
Finally, cells isolated from WSL-1/TRAMP knockout mice are
shown to retain their ability to interact with TWEAK. These
results suggest that WSL-1/TRAMP is not the major receptor
for TWEAK ß 2000 Federation of European Biochemical So-
cieties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
The tumour necrosis factor (TNF) ligand and receptor
superfamilies play a variety of key biological roles, including
regulation of apoptosis, cellular di¡erentiation and in£amma-
tion [1^6]. The ligands are mostly expressed as type 2 mem-
brane proteins, however many of these can also be produced
as soluble cytokines by proteolysis. The receptors are charac-
terised by the presence of a variable number of cysteine-rich
motifs in the extracellular domain. The cytoplasmic regions of
these receptors are much less conserved, except for a subgroup
characterised by the presence of an 80 amino acid death do-
main. This motif is responsible for recruiting the intracellular
signalling machinery leading in the case of apoptosis to acti-
vation of a caspase cascade [7].
Recently, database searching utilising conserved sequence
motifs and the application of techniques for studying pro-
tein^protein interactions has led to the discovery of many
new members of this family [1,3]. Several years ago, we and
others identi¢ed a novel death domain containing receptor
WSL-1/TRAMP (DR3, APO-3, LARD) [8^12], which has
preferential expression in tissues of the immune system. This
receptor is a potent inducer of apoptosis and can also activate
the transcription factor NF-UB. The extracellular domain of
this receptor failed to bind with known members of the ligand
family, suggesting that WSL-1/TRAMP had a novel cognate
ligand. It has been proposed since that the novel TNF family
member TWEAK is the ligand for WSL-1/TRAMP [13].
TWEAK has been previously identi¢ed as a weak inducer
of apoptosis, and can also mediate chemokine production
and endothelial cell proliferation [14^16]. Therefore we have
performed an extensive series of experiments to explore this
observation.
Firstly we performed a series of binding studies to deter-
mine the a⁄nity of WSL-1/TRAMP for a large panel of TNF-
related ligands, including TWEAK. Secondly we studied the
e¡ect of TWEAK on cells overexpressing the WSL-1/TRAMP
receptor. We also studied the e¡ect of TWEAK on several
untransfected cell lines including cells which do not express
WSL-1/TRAMP. Finally we cloned the murine TWEAK li-
gand and studied its binding to peripheral blood lymphocytes
from normal and WSL-1/TRAMP knockout mice.
2. Materials and methods
2.1. Constructs
The complete cDNA coding sequence for WSL-1/TRAMP was
cloned into pCDNA3 (Invitrogen). For the expression of soluble
mTWEAK and hTWEAK the sequence encoding the extracellular
region was cloned into pFLAG-CMV1 vector (Kodak-ABI) 3P to a
preprotrypsin leader sequence and FLAG epitope. Expression of the
receptor:Fc fusion protein has been previously described [11]. Ac-
tivation of NF-UB was studied using the promoter reporter con-
struct p(NF-UB)4-tk-sPAP, containing four UB response elements
(GGACTTTCC) upstream of the minimal thymidine kinase promoter
and the cDNA sequence for secreted placental alkaline phosphatase.
The extracellular domains of WSL-1/TRAMP (aa 1^181) and TRAIL-
R2 (aa 1^212) were fused to the C-terminal portion of TRAIL-R3
(aa 157^259) containing the TAPE repeats and GPI addition signal
sequence via a 3 aa. linker (VDK, SalI site). Stable clones were
established in 293 cells and positive clones were selected by FACS
staining.
2.2. Cell culture
HEK293, HEK293T, A375, HT29 cell lines were obtained from the
ATCC. The cells were cultured in Dulbecco’s minimal essential me-
dium (DMEM) (Gibco BRL Ltd), supplemented with 10% foetal calf
serum (FCS), 2 mM glutamine, penicillin (100 IU/ml), and strepto-
mycin (100 Wg/ml).
Primary murine cells used in the di¡erent studies were isolated from
blood (citrate plasma). In the FACS analysis cells were gated on
lymphocytes.
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2.3. Transfections
HEK293 and HEK293T cells were transfected using Lipofectamine
(Gibco BRL) according to the manufacturer’s protocol. For the
HEK293T cells transfected with WSL-1/TRAMP a total of 1.4 Wg
of DNA per well of a 6 well plate was used (6U105 cells). The amount
of pCDNA3/WSL-1 varied between 0 and 0.5 Wg per well, 0.4 Wg of
reporter construct p(NF-UB)4-tk-sPAP was used per well. The pro-
moter reporter construct RSV^lactamase was cotransfected, to control
for possible di¡erences in transfection e⁄ciency and to allow the
determination of the e¡ect of overexpression of WSL-1/TRAMP
on induction of apoptosis. The total amount of DNA in the trans-
fections was kept constant by the addition of the empty expression
vector.
For HEK293 cells 10 Wg pCMV1-FLAG-TWEAK plasmid per 75
cm2 £ask was used (70^80% con£uency).
SPAP and lactamase activity were quanti¢ed by standard colouri-
metric assay.
2.4. Puri¢cation of TWEAK protein
24 h after transfection of HEK293 cells with either murine or hu-
man TWEAK in pFLAG-CMV1, the medium was changed to the
serum free medium OPTIMEM. Following an additional 24 h incu-
Fig. 1. Recombinant TWEAK/Apo-3L does not bind TRAMP. A: Interaction of TNF ligands with TRAMP and TRAIL-R2. Wells of microti-
terplates were coated with TRAMP:Fc (white bars) and TRAIL-R2:Fc (black bars). Binding of the Flag-tagged-ligands (1 Wg/ml) was deter-
mined by the addition of anti-Flag M2 antibody followed by anti-mouse-HRP conjugate. The dose dependence of the TRAIL:TRAIL-R2 inter-
action was analysed by titration of TRAIL in the right panel. B: Lack of immunoprecipitation (IP) between TWEAK and TRAMP.
Recombinant TRAIL-R2:Fc or TRAMP:Fc (250 ng) were mixed with the indicated amounts of recombinant Flag-TRAIL and Flag-TWEAK
respectively and subsequently immunoprecipitated with PA-Sepharose. The IPs (upper panels) and supernatants (lower panels) were analysed by
anti-Flag Western blot. No binding was observed using unpuri¢ed TRAMP:Fc. C: TWEAK does not interact with TRAMP expressed at the
surface of cells. 293 cells stably transfected with either TRAMP:GPI (upper panels) or TRAIL-R2:GPI (lower panels) were stained with rabbit
anti-TRAMP polyclonal antibody (AL158), rabbit anti-TRAIL-R2 polyclonal antibody (AL142), Flag-TWEAK (100 ng) and Flag-TRAIL (100
ng). Polyclonal antibodies were revealed using anti-rabbit FabP2 coupled to ALEXA488 and Flag ligands were revealed using anti-Flag M2 fol-
lowed by anti-mouse FabP2 coupled to ALEXA488. The black histograms represent control staining either with non-speci¢c rabbit polyclonal
IgG (for TRAMP or TRAIL-R2) or absence of £agged ligand (Flag-TWEAK and Flag-TRAIL). The right panels show the dose^response
curves of the interactions.
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bation, the medium was harvested. The FLAG-tagged, secreted
TWEAK present in culture medium was puri¢ed using a M2-agarose
column (Sigma) according to the manufacturer’s protocol.
2.5. FACS analysis
2.5.1. WSL-1/TRAMP cell surface expression. Cells were har-
vested in cell dissociation bu¡er (Sigma). For the incubations with
antibodies, the bu¡er was changed to FACS bu¡er (PBS containing
2.5% FCS and 1% azide). 1U106 cells were incubated for 15 min at
RT in the presence or absence of 3 Wg rabbit polyclonal antibody
against WSL-1/TRAMP (Serotec). Cells were rinsed with FACS bu¡-
er and incubated for 15 min at RT with 0.5 Wg anti-rabbit Alexa 488.
After a ¢nal wash cells were resuspended in 0.5 ml FACS bu¡er and
analysed by £ow cytometry (Beckman-Coulter XL bench top £ow
cytometer).
2.5.2. TWEAK binding. For the binding of TWEAK to HT29 and
A375 cells the procedure is essentially as described above, with the
addition of an incubation in the presence or absence of the ligand. In
the ¢rst incubation cells were incubated for 10 min in the presence or
absence of 1^1000 ng per stain of FLAG-mTWEAK, FLAG-
hTWEAK or FLAG-hTRAIL. This is followed by a 10 min incuba-
tion, with 0.5 Wg anti-FLAG (M2, Sigma) and ¢nally a 10 min in-
cubation with 0.5 Wg anti-mouse Alexa 488.
For the TWEAK binding to primary murine cells, after the incu-
bation in the presence or absence of FLAG-mTWEAK (3 Wg per
incubation), cells were incubated with normal mouse serum to block
murine Fc-receptors and then stained with 0.5 Wg anti-FLAG conju-
gated to biotin (M2-biotin, Sigma). In the last incubation 0.5 Wg
Streptavidin Alexa 488 was used.
2.5.3. Double staining of murine cells. To identify cell types bind-
ing to TWEAK, ligand binding studies were performed as described
above, with the addition in the last incubation of phycoerythrin con-
jugates of antibodies (0.4 Wg for each conjugate) for cell speci¢c pro-
teins (anti-CD3, T-cells; anti-CD45-R, B-cells; anti-CD14, mono-
cytes/macrophages). Hamster IgG2A-PE was used as an isotype
control and normal mouse serum was added to block murine Fc-
receptors.
2.6. In vitro binding assays
2.6.1. Ligand binding ELISA. Wells of 96 well ELISA plates
(Nunc Maxisorp, 439454) were coated with various receptor:Fc re-
combinant fusion constructs (1 Wg/ml in PBS, 100 Wl, 2^16 h, 37‡C).
After saturation in block bu¡er (PBS containing 5% FCS, 1 h, 37‡C)
and three washes (PBS containing 0.05% Tween 20) using an ELISA
washer, Flag-tagged ligands were added (1 Wg/ml in PBS containing
0.5% FCS, 100 Wl, 1 h, 37‡C) and serially diluted in PBS as indicated.
After three washes (PBS, 0.05% Tween-20) bound ligands were re-
vealed with anti-Flag M2 antibody (1 Wg/ml in block bu¡er, 100 Wl,
30 min, 37‡C), rabbit anti-mouse IgG coupled to peroxidase (1/1000
dilution in block bu¡er, 100 Wl, 30 min, 37‡C) and o-phenylenedi-
amine hydrochloride (0.3 mg/ml in 50 mM citric acid, 100 mM
Na2HPO4, 0.01% H2O2). The plate was washed four times between
each step of the detection. Absorbance was measured at 490 nm with
an ELISA reader.
2.6.2. Immunoprecipitation. 250 ng of puri¢ed recombinant
TRAMP:Fc or TRAIL-R2:Fc were mixed with 1, 10, 100, 250 and
500 ng Flag-TRAIL or Flag-TWEAK in 200 Wl of PBS containing 10
Wg BSA. The mixture was precleared for 1 h on 10 Wl Sepharose-6B
beads and the supernatant was immunoprecipitated overnight with 10
Wl PA-Sepharose. The beads were washed three times with 500 Wl PBS
and proteins were eluted by boiling 5 min in SDS sample bu¡er con-
taining 100 mM DTT and analysed by SDS^PAGE and Western blot.
2.7. IL-8 ELISA
IL-8 protein was measured using a standard ELISA procedure.
3. Results
3.1. Interaction of WSL-1/TRAMP with TNF family ligands
It has been shown previously, using an ELISA-based in
vitro assay, that TRAMP does not interact with FasL,
TRAIL and LTK1L2. This initial experiment was repeated,
using a larger panel of TNF-related ligands, including the
recently characterised BAFF, APRIL, TRANCE/RANKL,
LIGHT and TWEAK. No signi¢cant binding of any of these
ligands to WSL-1/TRAMP was observed, while TRAIL bind-
ing to TRAIL-R2 was easily detected under the same set of
conditions (Fig. 1A). To exclude the possibility that the
TWEAK-WSL-1/TRAMP interaction is of low a⁄nity, and
hence only detectable at very high ligand concentrations, a
titration experiment was performed using the same setup. In
our hands, no TWEAK binding to TRAMP was detected at
ligand concentrations as high as 1 Wg/ml, whereas 20-fold
lower TRAIL concentrations were already su⁄cient to yield
a saturating signal on TRAIL-R2 (Fig. 1A). Puri¢cation of
Fig. 2. TWEAK has no e¡ect on apoptosis or NF-UB activation
induced by WSL-1/TRAMP. HEK293T cells were transfected with
the indicated concentrations of a pCDNA3 WSL-1 expression vec-
tor in the presence or absence of recombinant TNFK or TWEAK
(10 ng/ml). After 16 h incubation alkaline phosphatase activity was
measured using a colourimetric assay (A), apoptosis (B) was esti-
mated by propidium iodide staining and FACS analysis.
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TRAMP:Fc or its adsorption to plastic might result in its
denaturation and loss of binding capacity, and thus a parallel
binding experiment was performed using recombinant
TRAMP:Fc (puri¢ed or as crude cell supernatant) and
Flag-tagged TWEAK in solution. Consistent with the ELISA
assay, no TWEAK was co-immunoprecipitated using
TRAMP:Fc whereas TRAIL e⁄ciently bound to TRAIL-
R2:Fc (Fig. 1B). Finally, ligand binding was performed on
HEK 293 clones, stably transfected with expression vectors
encoding glycosylphosphatidylinositol (GPI)-anchored recep-
tor fusion proteins. Surface expression of TRAMP:GPI and
TRAIL-R2:GPI was analysed by £ow cytometry using poly-
clonal anti-TRAIL-R2 and anti-TRAMP antibodies (Fig.
1C). It is noteworthy that the TRAMP:GPI expressing clone
displayed signi¢cant staining for TRAIL-R2, probably re£ect-
ing the endogenous level of TRAIL-R2. Both clones were not
stained with Flag-TWEAK, whereas Flag-TRAIL staining
correlated completely with TRAIL-R2 expression levels on
both clones as detected by anti-TRAIL-R2 antibodies.
3.2. Interaction of TWEAK with WSL-1/TRAMP expressing
cells
Both TWEAK and WSL-1/TRAMP are capable of activat-
ing NF-UB and inducing apoptosis [8,11,16], and it has been
previously reported that transfection of WSL-1 (Apo 3) into
HEK293 cells sensitises these cells to apoptosis mediated by
TWEAK [5]. HEK293T cells were transfected with varying
Fig. 4. Binding of TWEAK and WSL-1 to A375 and HT29 cells. Cells were incubated for 10 min in the presence (black histogram) or absence
(dotted histogram) of 1 Wg FLAG-tagged murine or human TWEAK (A and B). This was followed by a 10 min incubation with 0.5 Wg anti-
FLAG antibody and ¢nally a 10 min incubation with 0.5 Wg anti-mouse Alexa488. For WSl-1 binding (C and D) the cells were incubated for
10 min with 3 Wg rabbit polyclonal anti -WSL-1/TRAMP antibody (black histogram). This was followed by a 10 min incubation with 0.5 Wg
anti-rabbit Alexa488. In all cases the cells were then washed in FACS bu¡er and analysed by £ow cytometry. Control were treated in the same
way, except that anti-WSL-1 was omitted (dotted histogram).
Fig. 3. Transfected WSL-1/TRAMP is expressed on the cell surface
of HEK293T cells. 20 h following transfection of 6U105 293T cells
with 0.1 Wg pCDNA3 WSL-1 expression construct the cells were
harvested and stained with rabbit polyclonal anti-WSL-1/DR3 and
the stained cells detected by £ow cytometry (black histogram). Con-
trol untransfected cells were treated similarly (dotted histogram).
FEBS 24321 17-11-00
A. Kaptein et al./FEBS Letters 485 (2000) 135^141138
concentrations of a WSL-1/TRAMP expression vector and
NF-UB activation and apoptosis determined following treat-
ment with or without recombinant TWEAK or TNFK. As
shown in Fig. 2, the transfection with WSL-1/TRAMP in-
duced the activation of NF-UB and at higher concentrations
of the expression vector increasing levels of apoptosis were
induced. Treatment with TWEAK had no e¡ect on the acti-
vation of NF-UB or apoptosis induced by WSL-1/TRAMP.
WSL-1 and TNF-R1 are reported to use the same intracellu-
lar signalling molecules. Incubation with TNFK resulted in a
strong activation of NF-UB in the presence or absence of
WSL-1, indicating that the signalling pathways downstream
of WSL-1 and TNFR1 are functional in these cells. NF-UB
activation by TNFK was decreased at higher concentration of
the WSL-1/TRAMP expression vector because of WSL-1-in-
duced apoptosis. Expression of WSL-1/TRAMP on the cell
surface of the transfected 293T cells was con¢rmed by FACS
analysis using a polyclonal antibody against WSL-1 (Fig. 3)
and therefore does not explain why we did not observe the
previously reported synergistic e¡ect of TWEAK and WSL-1
on apoptosis.
3.3. Interaction of TWEAK with A375 and HT29 cells
In order to establish that the recombinant TWEAK was
biologically active, we treated HT29 and A375 cells with
TWEAK and observed the expected stimulation of IL-8 (Ta-
ble 1). Additionally we observed rapid induction of apoptosis
in HT29 cells treated with TWEAK in the presence of inter-
feron Q (data not shown). Binding of murine TWEAK to both
A375 and HT29 cells was observed (Fig. 4a,b), identical re-
sults were found with recombinant human TWEAK (data not
shown). In particular, strong binding to A375 cells was ob-
served. To establish the presence of the WSL-1/TRAMP re-
ceptor on the surface of these cells we used an antibody
against the extracellular domain of WSL-1, and observed
that the receptor is only expressed on the surface of HT29
cells (Fig. 4c,d).
These observations, namely the strong binding and biolog-
ical activity of TWEAK in A375 cells, which do not express
the WSL-1/TRAMP receptor, suggest that there is either an-
other receptor for TWEAK on A375 cells, or that WSL-1/
TRAMP is not the true TWEAK receptor. Therefore we
chose to extend these studies into a system where we could
study the e¡ect of TWEAK in the complete absence of WSL-
1/TRAMP.
3.4. Binding of murine TWEAK to peripheral blood
lymphocytes from wild-type and WSL-1/TRAMP
knockout mice
Knockout mice in which the WSL-1/TRAMP receptor is
deleted have been generated (submitted for publication). Pe-
ripheral blood lymphocytes from both wild-type and homo-
zygous mice were isolated and TWEAK binding studies per-
formed. No signi¢cant di¡erences were observed in the ability
of TWEAK to bind to either WSL-1 +/+, +/3 or 3/3 PBL’s
(Fig. 5). Positive binding percentages were 34, 21 and 29%
respectively. Further analysis was performed to establish
which cells bound to TWEAK in these experiments. Utilising
Fig. 5. TWEAK binds to both murine wild-type and WSL-1/
TRAMP knockout cells. Peripheral blood lymphocytes from wild-
type and wsl-1 knockout mice were incubated for 10 min in the
presence or absence of FLAG-tagged murine TWEAK (3 Wg). Cells
were then incubated with 0.5 Wg anti-FLAG conjugated to biotin,
following the blocking of murine Fc receptors with normal mouse
serum. Finally the cells were incubated with 0.5 Wg Streptavidin
Alexa488, washed in FACS bu¡er and analysed by £ow cytometry.
Table 1
IL-8 concentration medium (pg/ml)
HT29 cells A375 cells
3TWEAK +TWEAK 3TWEAK +TWEAK
0^24 h 718 999 230 584
24^48 h 778 970 278 614
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the cell type speci¢c surface marker anti-CD3 we observed no
interaction with T-lymphocytes (Fig. 6). However analysis us-
ing anti-CD45r showed that TWEAK is interacting with a
subpopulation of B-cells (Fig. 6). Strong interaction with mac-
rophages was also observed, as was weaker binding to gran-
ulocytes (data not shown). No di¡erences in the type of
TWEAK-binding cells were observed between wild-type and
knockout animals (data not shown).
Taken together these observations indicate that TWEAK
exhibits a normal binding pro¢le in several di¡erent cell types
isolated from a knockout animal in which its proposed recep-
tor has been deleted. The data suggest that the TWEAK li-
gand has a receptor that is not WSL-1/TRAMP, and WSL-1/
TRAMP may have as yet unidenti¢ed ligand distinct from
TWEAK.
4. Discussion
The continuing identi¢cation of numerous new genes re-
lated to both TNF and the TNF receptor highlights the bio-
logical importance of these gene families. The subgroup of
receptors that contain a cytoplasmic death domain is of par-
ticular interest as a result of their ability to regulate apoptosis
and the activation of NF-UB, events of great biological sig-
ni¢cance. Death domain containing receptors such as the
TNF receptor and FAS have all been shown to be involved
in the pathology of human disease, therefore the biological
role of the WSL-1/TRAMP receptor is also of considerable
interest. In particular its predominant expression in cells from
the immune system suggests an important function, and dele-
tion of the chromosomal locus containing the WSL-1/
TRAMP gene has been associated with neuroblastoma [17].
The determination of the biological function of WSL-1/
TRAMP has been signi¢cantly hindered by the lack of its
cognate ligand, so the report that the novel TNF-related mol-
ecule TWEAK could bind to the receptor promised to be an
important breakthrough [13]. However there appeared to be
several discrepancies between the previously published data
on TWEAK and the function and distribution of the WSL-
1/TRAMP receptor. For example, Chicheportiche et al. [16]
reported preliminary results that TWEAK did not bind WSL-
1/TRAMP and Schneider et al. [14] found that Kym-1 cells
bound TWEAK but did not express WSL-1/TRAMP.
Analysis of the interaction between WSL-1 and members of
the TNF ligand family (including TWEAK) by ELISA, im-
mune precipitation or binding to cells transfected with a
WSL-1/TRAMP construct, could not reproduce the in vitro
binding previously reported [5]. In a series of experiments
utilising both human and murine TWEAK ligand, it has
been shown that the TWEAK protein has no e¡ect on exper-
imental cell lines transfected with WSL-1/TRAMP, again in
contrast to previously reported results which suggested
TWEAK increased WSL-1 mediated apoptosis [5]. The data
also demonstrate that TWEAK can bind strongly to cells
that do not express WSL-1/TRAMP on the cell surface, sug-
gesting strongly the presence of a di¡erent TWEAK receptor
on these cells. Biological activity of TWEAK is also observed
in these cells, despite the absence of the proposed receptor.
Finally, various cell types isolated from mice in which the
WSL-1/TRAMP receptor has been deleted have been shown
to retain their wild-type ability to interact with the TWEAK
ligand.
Taken together, biochemical interaction studies and data
obtained with knockout mice strongly suggest that TWEAK
is not the ligand for the death domain containing receptor
WSL-1/TRAMP. Therefore it is unlikely that WSL-1/
TRAMP plays a role in the biological function of TWEAK.
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